Out-of-Pocket Prescription Drug Savings for Medicare Beneficiaries with Asthma and COPD Under the Inflation Reduction Act

被引:0
|
作者
Mein, Stephen A. [1 ,2 ,3 ]
Tale, Archana [1 ,2 ]
Rice, Mary B. [3 ]
Narasimmaraj, Prihatha R. [1 ,2 ]
Wadhera, Rishi K. [1 ,2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res, Boston, MA 02215 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
asthma; chronic obstructive pulmonary disease; health policy; medicare; health care costs; UNITED-STATES; ADHERENCE; INHALERS; NONADHERENCE; IMPACT; COSTS; CARE;
D O I
10.1007/s11606-024-09063-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: High and rising prescription drug costs for asthma and chronic obstructive pulmonary disease (COPD) contribute to medication nonadherence and poor clinical outcomes. The recently enacted Inflation Reduction Act includes provisions that will cap out-of-pocket prescription drug spending at $2,000 per year and expand low-income subsidies. However, little is known about how these provisions will impact out-of-pocket drug spending for Medicare beneficiaries with asthma and COPD. Objective: To estimate the impact of the Inflation Reduction Act's out-of-pocket spending cap and expansion of low-income subsidies on Medicare beneficiaries with obstructive lung disease. Design: We calculated the number of Medicare beneficiaries >= 65 years with asthma and/or COPD and out-of-pocket prescription drug spending > $2,000/year, and then estimated their median annual out-of-pocket savings under the Inflation Reduction Act's spending cap. We then estimated the number of beneficiaries with incomes > 135% and <= 150% of the federal poverty level who would become newly eligible for low-income subsidies under this policy. Participants: Respondents to the 2016-2019 Medical Expenditure Panel Survey (MEPS). Main MeasuresAnnual out-of-pocket prescription drug spending. Key Results: An annual estimated 5.2 million Medicare beneficiaries had asthma and/or COPD. Among them, 360,160 (SE +/- 38,021) experienced out-of-pocket drug spending > $2,000/year, with median out-of-pocket costs of $3,003/year (IQR $2,360-$3,941). Therefore, median savings under the Inflation Reduction Act's spending cap would be $1,003/year (IQR $360-$1,941), including $738/year and $1,137/year for beneficiaries with asthma and COPD, respectively. Total annual estimated savings would be $504 million (SE +/- $42 M). In addition, 232,155 (SE +/- 4,624) beneficiaries would newly qualify for low-income subsidies, which will further reduce prescription drug costs. Conclusions: The Inflation Reduction Act will have major implications on out-of-pocket prescription drug spending for Medicare beneficiaries with obstructive lung disease resulting in half-a-billion dollars in total out-of-pocket savings per year, which could ultimately have implications on medication adherence and clinical outcomes.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Impact of Medicare Part D on Out-of-Pocket Prescription Drug Costs among Elderly with Diabetes
    Choi, Yoon Jeong
    Jia, Haomiao
    Gross, Tal
    Weinger, Katie
    Stone, Patricia W.
    Smaldone, Arlene M.
    [J]. DIABETES, 2015, 64 : A70 - A70
  • [32] POTENTIAL OUT-OF-POCKET SAVINGS FOR DUAL -ELIGIBLE BENEFICIARIES WITH DEVELOPMENTAL DISABILITIES AFTER MEDICARE PART D PLAN OPTIMIZATION
    Li, H.
    Patel, R.
    Rogan, E.
    Valle-Oseguera, C. S.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A284 - A284
  • [33] Medicare Part D take up and changes in out-of-pocket prescription costs and use among beneficiaries with cardiovascular disease
    Doshi, Jalpa A.
    Patel, Ashwinkumar
    Cen, Liyi
    [J]. CIRCULATION, 2008, 117 (21) : E451 - E451
  • [34] Changes in Out-of-Pocket Spending for Common Oral Cancer Medications After the Inflation Reduction Act
    Pockros, Benjamin
    Ellimoottil, Chad
    Sbei, Belal
    Caram, Megan
    Stensland, Kristian
    [J]. JAMA NETWORK OPEN, 2024, 7 (09)
  • [35] ASSESSING COST-SAVINGS FROM THE INFLATION REDUCTION ACT IN LOUISIANA MEDICARE BENEFICIARIES DUE TO DIABETES MEDICATIONS
    Winberg, D.
    Xuan, D.
    Tang, T.
    Shi, L.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S248 - S248
  • [36] Out-of-pocket costs of oral anticancer drugs for Medicare beneficiaries vary by strength and formulation
    Gupta, Arjun
    Arora, Nivedita
    Haque, Waqas
    Hussaini, S. M. Qasim
    Sedhom, Ramy
    Blaes, Anne H.
    Dusetzina, Stacie B.
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (01)
  • [37] Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries
    Gross, DJ
    Alecxih, L
    Gibson, MJ
    Corea, J
    Caplan, C
    Brangan, N
    [J]. HEALTH SERVICES RESEARCH, 1999, 34 (01) : 241 - 254
  • [38] Out-of-pocket (OOP) health care expenditure burden for Medicare beneficiaries with cancer.
    Zuckerman, Ilene H.
    Pandya, Naimish B.
    Stuart, Bruce C.
    Shaffer, Thomas
    Erten, Mujde Z.
    Ke, Xuehua
    Shoemaker, J. Samantha
    Tai, Ming-Hui
    Davidoff, Amy J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Out-of-pocket drug costs before and after the Medicare Modernization Act: Are there differences in how people fare?
    Gellad, WF
    Huskamp, HA
    Phillips, KA
    Haas, JS
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 : 138 - 138
  • [40] ARE OUT-OF-POCKET COSTS UNDER MEDICARE A DETERRENT TO SCREENING COLONOSCOPY?
    Li, Joy
    Cooper, Gregory S.
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S947 - S947